In yesterday’s Wall Street session, Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares traded at $104.14, up 0.68% from the previous session.
As of this writing, 26 analysts cover Neurocrine Biosciences Inc. (NASDAQ:NBIX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $150.00 and a low of $95.00, we find $125.00. Given the previous closing price of $103.44, this indicates a potential upside of 20.84 percent. NBIX stock price is now 8.70% away from the 50-day moving average and -1.19% away from the 200-day moving average. The market capitalization of the company currently stands at $10.01B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 7 analysts who have given it a hold rating, whereas 16 have given it a buy rating. Brokers who have rated the stock have averaged $126.08 as their price target over the next twelve months.
With the price target enhanced from $115 to $125, SVB Securities Upgraded its rating from Market Perform to Outperform for Neurocrine Biosciences Inc. (NASDAQ: NBIX).
In other news, Cooke Julie, Chief Human Resources Officer sold 11,397 shares of the company’s stock on May 01. The stock was sold for $1,184,049 at an average price of $103.89. Upon completion of the transaction, the Chief Human Resources Officer now directly owns 16,169 shares in the company, valued at $1.68 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01, Director RASTETTER WILLIAM H sold 4,300 shares of the business’s stock. A total of $436,135 was realized by selling the stock at an average price of $101.43. This leaves the insider owning 42,785 shares of the company worth $4.46 million. Insiders disposed of 476,653 shares of company stock worth roughly $49.64 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NBIX stock. A new stake in Neurocrine Biosciences Inc. shares was purchased by BRAIDWELL LP during the first quarter worth $79,855,000. LOGOS GLOBAL MANAGEMENT LP invested $20,828,000 in shares of NBIX during the first quarter. In the first quarter, LOOMIS SAYLES & CO L P acquired a new stake in Neurocrine Biosciences Inc. valued at approximately $16,975,000. PROSIGHT MANAGEMENT, LP acquired a new stake in NBIX for approximately $8,331,000. BRIDGEWATER ASSOCIATES, LP purchased a new stake in NBIX valued at around $6,166,000 in the second quarter.
Wednesday morning saw Neurocrine Biosciences Inc. (NASDAQ: NBIX) opened at $103.61. During the past 12 months, Neurocrine Biosciences Inc. has had a low of $89.04 and a high of $129.29. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 3.80, and a quick ratio of 3.70. According to the stock market information, the enterprise value for the company is $9.46B, which is based on a 170.72 price-to-earnings ratio, a 7.17 price-to-earnings-growth ratio, and a beta of 0.47. The fifty day moving average price for NBIX is $96.01 and a two-hundred day moving average price translates $105.36 for the stock.
According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.95, beating analysts’ expectations of $0.78 by 0.17. This compares to -$0.18 EPS in the same period last year. The net profit margin was 4.00% and return on equity was 4.00% for NBIX. The company reported revenue of $452.7 million for the quarter, compared to $378.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 19.7 percent. For the current quarter, analysts expect NBIX to generate $472.66M in revenue.
